article thumbnail

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

pharmaphorum

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.

article thumbnail

Merck’s Welireg becomes first drug for rare VHL tumours in US

pharmaphorum

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 This first FDA approval triggers a $50 million payment to former Peloton shareholders, with another $50 million due on commercial launch. Merck paid $1.05 billion in milestone payments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

#ASH22: Pirtobrutinib emerges as an option for Richter’s Transformation

Pharmaceutical Technology

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8

article thumbnail

Eliquis generic availability, cost, and dosage

The Checkup by Singlecare

Food and Drug Administration (FDA) in 2012 as a brand-name drug. Although a generic was approved in 2019, generic apixaban will not be available on the market until at least April 2028. The FDA approved two applications for generic versions of Eliquis by the companies Micro Labs Limited and Mylan Pharmaceuticals, Inc.

Dosage 52
article thumbnail

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

Previously, J&J’s/Legend Biotech’s Carvykti (cilta-cel) and Bristol Myers Squibb’s (BMS) Abecma (ide-cel), anti-BCMA chimeric antigen receptor (CAR) T-cells, were approved by both the EMA and the US Food and Drug Administration (FDA) for R/R MM. Should CAR-T cells, or antibodies be used first?

FDA 59
article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

The FDA Law Blog

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. Final Guidance at 2. of the total expenditures for all Part D drugs in 2021.

Labelling 105
article thumbnail

Proposed LDT Rule Raises Many Questions but Provides Few Answers

The FDA Law Blog

Javitt & Philip Won — As we reported last week, FDA has issued a 26 page, single spaced, tiny-font Proposed Rule of Laboratory Developed Tests (LDTs). The brevity of this change belies the foreseeably seismic impact of FDA regulation of clinical laboratories on the healthcare system. By Allyson B. Mullen & Gail H.

FDA 64